Brief: ALK-Abello Announces Successful Outcome Of Phase 2 Trial Of Peanut Allergy Tablet
20/04/2026 13:56
April 20 (Reuters) - ALK-Abello A/S ALKb.CO: ALK ANNOUNCES SUCCESSFUL OUTCOME OF PHASE 2 TRIAL WITH ITS TABLET FOR TREATMENT OF PEANUT ALLERGY DEMONSTRATING EARLY ONSET OF EFFICACY 49% ON HIGHEST DOSE TOLERATED 300 MG PEANUT PROTEIN VERSUS. 18% PLACEBO 31% ON HIGHEST DOSE TOLERATED 600 MG PEANUT PROTEIN VERSUS. 8% PLACEBO PEANUT TABLET TREATMENT SAFE WITH LOW DISCONTINUATIONS AND NO SERIOUS ADVERSE EVENTS PHASE 3 DEVELOPMENT EXPECTED TO BEGIN LATE 2026 22% ON HIGHEST DOSE TOLERATED 1,000 MG PEANUT PROTEIN VERSUS. 2% PLACEBO Source text: ID:nGNE4Rc9TR Further company coverage: [ALKb.CO] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))